Beta-blocker goes on trial as asthma therapy
نویسندگان
چکیده
منابع مشابه
Beta-Blocker Therapy in Noncardiac Surgery
Perioperative myocardial infarction is a major cause of complications and death among patients undergoing noncardiac surgery. 1 Annually in the United States, approximately 27 million patients are given anesthesia for surgical procedures; of these, approximately 50,000 patients have a perioperative myocardial infarction. 2 The pathophysiology of an acute perioperative myocardial infarction is p...
متن کاملBeta-blocker therapy in non-cardiac surgery.
Perioperative myocardial infarction is a major cause of complications and death among patients undergoing noncardiac surgery. 1 Annually in the United States, approximately 27 million patients are given anesthesia for surgical procedures; of these, approximately 50,000 patients have a perioperative myocardial infarction. 2 The pathophysiology of an acute perioperative myocardial infarction is p...
متن کاملOutpatient adherence to beta-blocker therapy after acute myocardial infarction.
OBJECTIVES This study was designed to determine adherence to outpatient beta-blocker therapy following acute myocardial infarction (AMI). BACKGROUND The importance of beta-blocker therapy after AMI is widely recognized. Outpatient adherence with this recommendation, however, is not well described. METHODS Data on 846 patients surviving AMI were studied. Factors associated with filling a bet...
متن کاملAutonomic dysfunction and beta blocker therapy in Chagas heart disease
In a hamster model of Chagas disease, Pimentel et al. (1) recently found that 1) carvedilol decreased mortality in the acute, but not in the chronic stage and 2) in the chronic stage, carvedilol neither changed the left ventricular diameter and/or function, nor attenuated changes in the resting electrocardiogram (ECG), nor decreased the myocardial collagen content. In contrast, we did not obser...
متن کاملNovel insights into beta-blocker therapy for long QT syndromes.
The congenital long QT syndromes (LQTS [cumulative incidence 1:2,000]) are individually distinct but exhibit a common phenotype of QT-interval prolongation and sudden death risk. Potassium channel mutations, KCNQ1 (LQTS1) and KCNH2 (LQTS2), account for approximately 60% of cases. Beta-blockers have long been the mainstay of therapy, dramatically reducing syncope and death (1). Pharmacologically...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 2004
ISSN: 0028-0836,1476-4687
DOI: 10.1038/432007a